Purpose

Engage stakeholders in an analysis of the medical unmet need for the essential maternal health medicines and the factors that contribute to it

Improve future procurement planning
Rationale for the Approach

• Decisions regarding the procurement are not evidence based
  • No country specific morbidity/incidence data available
  • Consumption data is not available and so distribution data is used
• No real idea of sufficiency of the amounts of these medicines currently available
Step 1. Demographic Data

Number of births/pregnancies in a year

- Percentage of facility based deliveries
  - Private sector deliveries
  - Public sector deliveries
- Percentage of home deliveries
Step 2. Epidemiological Assumptions

In the absence of country specific morbidity data, use available data from published scientific literature
PREVENTION AND TREATMENT OF PPH

Number of births

Facility-based births

Use oxytocin

100% of all facility-based deliveries require 10 IU oxytocin for prevention of PPH.

Use misoprostol

100% of home deliveries require 600 μg of misoprostol for prevention of PPH.

Home-based births

Use oxytocin

2.85% of women who receive oxytocin for PPH prevention might develop PPH each require 70 IU oxytocin.

6% of those who receive misoprostol for PPH prevention might develop PPH each requiring up to 70 IU oxytocin.
2-3% of pregnancies are complicated by PE/E

Each case of PE/E will require up to 45 g of MgSO₄ injection for management
Induction Of Labor

9.6% of deliveries are induced and may require oxytocin 10 IU

Or alternatively use misoprostol 25 μg

Augmentation of Labor

About 20% of deliveries end up in prolonged labor and may require Oxytocin 10 IU

Or alternatively use misoprostol 25 μg
10–15% of pregnancies end up in miscarriages

28% of miscarriage cases are managed expectantly may be given misoprostol

Each case will require 600 μg misoprostol
### Step 3: Calculate Estimated Need—Oxytocin

<table>
<thead>
<tr>
<th>Indication</th>
<th>Amount Required</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Induction</strong> (9.6% of facility based deliveries)</td>
<td>84,578</td>
</tr>
<tr>
<td><strong>Augmentation</strong> (20% of facility based deliveries)</td>
<td>176,204</td>
</tr>
<tr>
<td><strong>Prevention of PPH</strong> (100% of facility deliveries)</td>
<td>881,020</td>
</tr>
<tr>
<td><strong>Treatment of PPH after receiving oxytocin</strong> (2.85% of facility based deliveries)</td>
<td>175,763</td>
</tr>
<tr>
<td><strong>Treatment of PPH after receiving oxytocin</strong> (6% of home deliveries)</td>
<td>905,932</td>
</tr>
<tr>
<td><strong>Total need</strong></td>
<td>22,223,497</td>
</tr>
<tr>
<td><strong>Three month buffer stock</strong></td>
<td>555,874</td>
</tr>
<tr>
<td><strong>Total estimated need</strong></td>
<td>2,779,371</td>
</tr>
</tbody>
</table>

a = Country A with 29% facility based deliveries
# Calculation—Public/Private Sector

From DHS Survey | Total facilities, by location, % | Type of facility, % | Oxytocin |
---|---|---|---|
Facility based deliveries | 29 | | |
  • Public Sector 12% | | 41 | 1,139,542 |
  • Private Sector 17% | | 59 | 1,639,829 |
Home deliveries | 71 | | |
Total | 100 | | 2,779,371 |
Step 4. Collect Procurement Data

- Collect data on formulation, amount procured and period expected to cover from
  - National/central level
  - Sub- national level
Step 5. Compare Data for Public sector-Oxytocin

<table>
<thead>
<tr>
<th>Estimated yearly need for oxytocin</th>
<th>Country procurement plan for oxytocin</th>
<th>Percentage unmet need for oxytocin</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,139,542</td>
<td>136,875</td>
<td>88%</td>
</tr>
</tbody>
</table>

- What are we assuming for 88% of requirement of oxytocin
- Role of private sector
Step 6. Revise Procurement Plan and Develop Action Plan

• Establish a stakeholder convening group
• Two-day consultative meeting
  • Day 1:
    • Review theoretical need
    • Agree on the assumptions used
    • Collect and review current procurement plan
  • Day 2:
    • Agree on action plan (% of unmet need coverage for next 3 years)
    • Revise country procurement plan
Way forward

- The draft document and the assumptions have been shared at a technical group meeting
- SIAPS will be field testing the tool in 2-3 countries
- The tool will be available to countries for use once field testing is completed

Stay tuned!